Torsdag 26 Februari | 03:30:05 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-11-12 07:00 Kvartalsrapport 2026-Q3
2026-08-19 07:00 Kvartalsrapport 2026-Q2
2026-05-14 07:00 Kvartalsrapport 2026-Q1
2026-04-23 N/A Årsstämma
2026-03-03 07:00 Bokslutskommuniké 2025
2026-01-02 - Extra Bolagsstämma 2026
2025-11-12 - Extra Bolagsstämma 2025
2025-11-12 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-28 - X-dag ordinarie utdelning LIFE 0.00 NOK
2025-04-25 - Årsstämma
2025-02-20 - Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-10-01 - Split LIFE 13:1
2024-08-27 - Kvartalsrapport 2024-Q2
2024-05-16 - Extra Bolagsstämma 2024
2024-05-08 - Kvartalsrapport 2024-Q1
2024-05-02 - X-dag ordinarie utdelning LIFE 0.00 NOK
2024-04-30 - Årsstämma
2024-02-27 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-05-08 - X-dag ordinarie utdelning LIFE 0.00 NOK
2023-04-18 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-09 - X-dag ordinarie utdelning LIFE 0.00 NOK
2022-05-06 - Årsstämma
2022-04-21 - Bokslutskommuniké 2021
2021-09-30 - Extra Bolagsstämma 2021
2021-08-05 - Kvartalsrapport 2021-Q2
2021-05-10 - X-dag ordinarie utdelning LIFE 0.00 NOK
2021-05-07 - Årsstämma
2021-04-20 - Bokslutskommuniké 2020
2020-06-26 - Årsstämma
2020-06-01 - Bokslutskommuniké 2019
2019-02-07 - Split LIFE 4:1
2018-12-11 - Extra Bolagsstämma 2018

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Lifecare är ett norskt bolag verksamt inom medicinteknik. Bolaget är specialiserat inom forskning och utveckling av microsensorer för diabetes. Mikrosensorerna injiceras under huden på patientens handled, och fungerar vidare som en realtidsuppdatering av glukosnivån i patienten. Utöver bidrar tekniken med larmsensor samt tillgång till historisk data över patientens glukosnivå. Bolaget etablerades under 2006 och har sitt huvudkontor i Bergen, Norge.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-02-25 07:00:00

Bergen, Norway, 25 February 2026 – Lifecare ASA (LIFE), a MedTech company developing next-generation implantable continuous glucose monitoring (CGM) technology, announces the appointment of Petter Nielsen as Chief Financial Officer (CFO). Nielsen will assume the position on 1 April 2026.

Nielsen succeeds Renete Kaarvik, who will step down from her role as CFO with her last working day on 31 March 2026.

Petter Nielsen brings extensive financial and capital markets experience from listed growth companies and international industrial groups. He most recently served as Group Chief Executive Officer of Gexcon AS (2022–2025), having previously held the position as Group Chief Financial Officer in the same company. Prior to that, he served as CFO of BerGenBio ASA, where he played a central role in the company’s listing on the Oslo Stock Exchange in 2017 and in raising significant equity and grant funding. He has also held senior finance roles in Vryhof/Deep Sea Mooring and Ernst & Young Transaction Advisory Services. 

Nielsen holds an MSc in Auditing and an MSc in Economics and Business Administration from the Norwegian School of Economics (NHH) and is a State Authorised Public Accountant. 

Joacim Holter, CEO of Lifecare, comments:
“Petter brings strong financial leadership experience from publicly listed growth companies and complex industrial organisations. His background in capital markets, regulatory reporting and strategic financing will be highly valuable as Lifecare moves into its next phase of clinical development and prepares for commercial scale-up.”

Holter continues:
“On behalf of the Board and management team, I would also like to thank Renete for her important contributions to Lifecare during a transformative period for the company, including strengthening our financial structure and supporting key development milestones.”

For further information, please contact:
Joacim Holter, CEO
Tel: +47 400 59 040
Email: joacim.holter@lifecare.no